Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older
- People newly diagnosed with a specific type of blood cancer called primary mediastinal large B-cell lymphoma, confirmed by a tissue biopsy analysed according to standard international guidelines (WHO 2016 classification)
- People at any stage of this condition (stages I through IV)
- People with any IPI score (a scoring system used to assess lymphoma severity), from 0 to 5
- People whose cancer involves the area in the middle of the chest (the mediastinum)
- People who have not yet received treatment, except for a short course of steroid medication (below a certain dose, for no more than 7 days) given in an emergency situation
- People whose treating team plans to start a specific chemotherapy regimen (R-CHOP-14 or R-ACVBP) guided by a type of imaging scan called PET-CT
- People whose pre-treatment PET-CT scan shows tumour activity above a certain level (a Deauville score of 4 or higher)
- People who have signed the informed consent form before any study procedures begin
- People who are covered by a social protection or health insurance plan
Who may not be able to join:
- People who have already started chemotherapy
- People for whom the FDG PET-CT scan (a type of nuclear imaging) is not medically suitable
- People whose cancer does not involve the chest (mediastinal) area
- People with a positive HIV test result
- People with active hepatitis B or C (positive test result combined with detectable levels of the virus)
- Adults who are under legal guardianship or a similar protective legal arrangement
- People who are pregnant or currently breastfeeding
- People who, for any reason, are unable to understand the study or follow its requirements (for example, due to language barriers, psychological difficulties, or geographical limitations)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: VINCENT CAMUS, MD, Centre Henri Becquerel
Phone: +33232082497
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Correlation between circulating tumoral DNA detection and complete molecular response
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.